Gadobutrol (Gadovist, BAY86-4875)

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
74
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Magnetic Resonance Imaging

Conditions

Magnetic Resonance Imaging

Trial Timeline

Sep 1, 2012 โ†’ Aug 1, 2013

About Gadobutrol (Gadovist, BAY86-4875)

Gadobutrol (Gadovist, BAY86-4875) is a phase 3 stage product being developed by Bayer for Magnetic Resonance Imaging. The current trial status is completed. This product is registered under clinical trial identifier NCT01660841. Target conditions include Magnetic Resonance Imaging.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (7)

NCT IDPhaseStatus
NCT01660841Phase 3Completed
NCT01344447Phase 3Completed
NCT01344460Phase 3Completed
NCT01095081Pre-clinicalCompleted
NCT00905879Pre-clinicalCompleted
NCT00874640Pre-clinicalCompleted
NCT00828737ApprovedCompleted